ASCO GU 2022: PROpel Suggests Adding Olaparib to Abiraterone Improves Outcomes in Castration-Resistant Prostate Cancer Regardless of Homologous Recombination Repair Status
But this interim analysis lacks overall survival data
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.